A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2024 Results of Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks, published in the Journal of the European Academy of Dermatology and Venereology
12 Mar 2024 Results of subgroup analysis assessing Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks presented at the American Academy of Dermatology annual Meeting 2024
12 Mar 2024 Interim Results of safety (data cutoff May 22, 2023) efficacy through 304 weeks of continuous risankizumab treatment, presented at the American Academy of Dermatology annual Meeting 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com